Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC

被引：0

作者：

Brazel, Danielle ^{[1
]}

Nagasaka, Misako ^{[2
,3
]}

机构：

[1] Scripps Green Hosp, Scripps Clin, Dept Hematol Oncol, 10166 N Torrey Pines Rd, La Jolla, CA 92037 USA

[2] Univ Calif Orange, Chao Family Canc Ctr, Irvine Sch Med, 101 City Dr, Orange, CA 92868 USA

[3] St Marianna Univ, Sch Med, Kawasaki, Japan

来源：

MED | 2024年 / 5卷 / 08期

关键词：

D O I：

10.1016/j.medj.2024.06.012

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%-50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS.

引用

页码：852 / 855

页数：4

共 50 条

[1] New territories: perioperative chemoimmunotherapy in early-stage NSCLC
Okuma, Yusuke
LANCET RESPIRATORY MEDICINE, 2025, 13 (02): : 102 - 103
[2] Perioperative nivolumab (NIVO) in patients (pts) with resectable stage IIeIIIB NSCLC: CheckMate 77T Chinese population analysis
He, J.
Wu, L.
Gao, Y.
Ying, K.
Jiang, G.
Lee, K-Y.
Chen, C.
Zhong, H.
Liu, S.
Xiong, F.
Chen, K-N.
Liu, L.
Tan, L.
Wang, W.
Shih, J-Y.
Sun, H.
Kang, W.
Zhang, H.
Lu, S.
ANNALS OF ONCOLOGY, 2024, 35 : S1616 - S1616
[3] Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816
Forde, P. M.
Peters, S.
Donington, J.
Meadows-Shropshire, S.
Tran, P.
Lucherini, S.
Erdmann, C. Coronado
Sun, H.
Cascone, T.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S2 - S2
[4] Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
Cascone, Tina
Provencio, Mariano
Sepesi, Boris
Lu, Shun
Aanur, Nivedita
Li, Sunney
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study
Provencio, Mariano
Awad, Mark M.
Spicer, Jonathan
Janssens, Annelies
Moiseenko, Fedor Vladimirovich
Gao, Yang
Watanabe, Yasutaka
Alexandru, Aurelia
Guisier, Florian
Frost, Nikolaj
Franke, Fabio A.
Hiltermann, T. Jeroen Jeroen Nicolaas
He, Jie
Tanaka, Fumihiro
Lu, Shun
Coronado Erdmann, Cinthya
Sathyanarayana, Padma
Tran, Phuong
Devas, Vipul
Cascone, Tina
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8007 - LBA8007
[6] Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study
Pulla, M. Provencio
Awad, M.
Cascone, T.
Spicer, J. D.
He, J.
Lu, S.
Alexandru, A.
Watanabe, Y.
Cornelissen, R.
Koch, L. D. O.
Kuzdzal, J.
Pujol, J-L.
Hoffknecht, P.
Gray, J. E.
Erdmann, C. Coronado
Neely, J.
Devas, V.
Bhatia, S.
Tanaka, F.
ANNALS OF ONCOLOGY, 2024, 35 : 1239 - 1240
[7] Early-stage NSCLC: perioperative strategies and approaches in the unresectable
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (SUPPL 5) : S82 - S86
[8] Surgery of Early-Stage NSCLC
Mueller, Michael
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S40 - S42
[9] The Role of Lymphadenectomy in Early-Stage NSCLC
Manfredini, Beatrice
Zirafa, Carmelina Cristina
Filosso, Pier Luigi
Stefani, Alessandro
Romano, Gaetano
Davini, Federico
Melfi, Franca
CANCERS, 2023, 15 (14)
[10] The Role of Radiotherapy in Early-Stage NSCLC
Senan, Suresh
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S42 - S43

← 1 2 3 4 5 →